Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
11.58
-0.42 (-3.50%)
At close: Mar 28, 2025, 4:00 PM
11.61
+0.03 (0.27%)
After-hours: Mar 28, 2025, 7:56 PM EDT
ARCT Employees
As of December 31, 2024, Arcturus Therapeutics Holdings had 176 total employees, including 174 full-time and 2 part-time employees. The number of employees decreased by 4 or -2.22% compared to the previous year.
Employees
176
Change (1Y)
-4
Growth (1Y)
-2.22%
Revenue / Employee
$865,398
Profits / Employee
-$459,892
Market Cap
314.05M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARCT News
- 24 days ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress - Business Wire
- 25 days ago - Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025 - Business Wire
- 4 weeks ago - Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 - Business Wire
- 6 weeks ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 7 weeks ago - Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire
- 2 months ago - Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 - Business Wire
- 2 months ago - Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - Business Wire